|
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |
|
|
|
|||||||||
|
|||||||||||
|
J Am Coll Cardiol, 1986; 8:18-26 © 1986 by the American College of Cardiology Foundation |
Atrial natriuretic factor, a peptide found in mammalian cardiac atria, has natriuretic and vasodilatory properties that may be important in the regulation of intravascular volume. To study factors related to its release in human subjects, intracardiac pressures and plasma atrial natriuretic factor concentrations in the central circulation were measured in 34 patients with a variety of cardiovascular disorders. Plasma atrial natriuretic factor concentration increased from the inferior vena cava to the right atrium (76 +/- 24 to 162 +/- 37 pg/ml, p less than 0.001) and from the vena cava to the aorta (76 +/- 24 to 177 +/- 46 pg/ml, p less than 0.001). Mean right atrial pressure was positively correlated with atrial natriuretic factor concentration in the pulmonary artery (r = 0.58, p less than 0.001), and mean pulmonary capillary wedge pressure was positively correlated with concentration in the aorta (r = 0.64, p less than 0.001). In six patients whose atrial natriuretic factor concentrations were measured at two different levels of atrial pressure, increased atrial pressure was accompanied by increased atrial natriuretic factor concentration in the pulmonary artery (p less than 0.01) and aorta (p less than 0.01). Atrial natriuretic factor levels measured in fresh myocardium from a patient undergoing cardiac transplantation showed tissue concentrations in the atria 500-fold higher than tissue concentrations in the ventricles. These data document that atrial natriuretic factor is found in human atrial myocardium and suggest that it may be released in response to increased atrial pressure. Such a secretory release mechanism is consistent with the hypothesis that atrial natriuretic factor plays a role in the regulation of circulatory volume.
This article has been cited by other articles:
|
|
 |
|
  K. K. Gaddam, M. K. Nishizaka, M. N. Pratt-Ubunama, E. Pimenta, I. Aban, S. Oparil, and D. A. Calhoun Characterization of Resistant Hypertension: Association Between Resistant Hypertension, Aldosterone, and Persistent Intravascular Volume Expansion Arch Intern Med, June 9, 2008; 168(11): 1159 - 1164. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Rodeheffer Measuring plasma B-type natriuretic peptide in heart failure: Good to go in 2004? J. Am. Coll. Cardiol., August 18, 2004; 44(4): 740 - 749. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C Briguori, S Betocchi, F Manganelli, B Gigante, M.A Losi, Q Ciampi, R Gottilla, A Violante, C.G Tocchetti, M Volpe, et al. Determinants and clinical significance of natriuretic peptides and hypertrophic cardiomyopathy Eur. Heart J., August 1, 2001; 22(15): 1328 - 1336. [Abstract] [PDF]
|
|
|
|
|
|
A. Rossi, M. Enriquez-Sarano, J. C. Burnett Jr., A. Lerman, M. D. Abel, and J. B. Seward Natriuretic peptide levels in atrial fibrillation: A prospective hormonal and Doppler-echocardiographic study J. Am. Coll. Cardiol., April 1, 2000; 35(5): 1256 - 1262. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Iervasi, A. Clerico, A. Pilo, L. Sabatino, C. Manfredi, F. Forini, M. G. Del Chicca, C. Palmieri, M. Ravani, and L. Donato Atrial Natriuretic Peptide Is Not Degraded by the Lungs in Humans J. Clin. Endocrinol. Metab., August 1, 1998; 83(8): 2898 - 2906. [Abstract] [Full Text]
|
|
|
|
 |
|
 A. Pilo, G. Iervasi, A. Clerico, F. Vitek, S. Berti, C. Palmieri, A. Biagini, and L. Donato Circulatory model in metabolic studies of rapidly renewed hormones: application to ANP kinetics Am J Physiol Endocrinol Metab, March 1, 1998; 274(3): E560 - E572. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-T. Shen, R. F. Woltmann, S. Appleby, S. Prahalada, S. M. Krause, S. D. Kivilghn, R. G. Johnson, P. K. Siegl, and J. J. Lynch Lack of beneficial effects of growth hormone treatment in conscious dogs during development of heart failure Am J Physiol Heart Circ Physiol, February 1, 1998; 274(2): H456 - H466. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Tsutamoto, A. Wada, K. Maeda, T. Hisanaga, Y. Maeda, D. Fukai, M. Ohnishi, Y. Sugimoto, and M. Kinoshita Attenuation of Compensation of Endogenous Cardiac Natriuretic Peptide System in Chronic Heart Failure : Prognostic Role of Plasma Brain Natriuretic Peptide Concentration in Patients With Chronic Symptomatic Left Ventricular Dysfunction Circulation, July 15, 1997; 96(2): 509 - 516. [Abstract] [Full Text]
|
|
|
|
|
|
C. R. Benedict, B. Shelton, D. E. Johnstone, G. Francis, B. Greenberg, M. Konstam, J. L. Probstfield, and S. Yusuf Prognostic Significance of Plasma Norepinephrine in Patients With Asymptomatic Left Ventricular Dysfunction Circulation, August 15, 1996; 94(4): 690 - 697. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. M. Stewart, M. H. Gewitz, P. K. Woolf, F. Niguidula, B. G. Fish, and G. A. Zeballos ELEVATED ARGININE VASOPRESSIN AND LOWERED ATRIAL NATRIURETIC FACTOR ASSOCIATED WITH HYPERTENSION IN COARCTATION OF THE AORTA J. Thorac. Cardiovasc. Surg., October 1, 1995; 110(4): 900 - 908. [Abstract] [Full Text]
|
|
|
|
|
|
G. Iervasi, A. Clerico, S. Berti, A. Pilo, A. Biagini, R. Bianchi, and L. Donato Altered Tissue Degradation and Distribution of Atrial Natriuretic Peptide in Patients With Idiopathic Dilated Cardiomyopathy and Its Relationship With Clinical Severity of the Disease and Sodium Handling Circulation, April 1, 1995; 91(7): 2018 - 2027. [Abstract] [Full Text]
|
|
|
|
 |
|
 H. Shimamoto and Y. Shimamoto Lisinopril Improves Aortic Compliance and Renal Flow : Comparison With Nifedipine Hypertension, March 1, 1995; 25(3): 327 - 334. [Abstract] [Full Text]
|
|
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |
